← back to search

Hang Xu

Chinese Academy of Medical Sciences & Peking Union Medical College · CN
Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include Cancer Genomics and Diagnostics, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, and Bladder and Urothelial Cancer Treatments.
h-index
34
citations
10,819
works
186
NIH funding
primary concept
Medicine
email

Recent publications

TRACERx analysis identifies a role for FAT1 in regulating chromosomal instability and whole-genome doubling via Hippo signalling.
2025cited by 7position: contributordoi
Senolysis Enabled by Senescent Cell‐Sensitive Bioorthogonal Tetrazine Ligation
Angewandte Chemie International Edition 2024cited by 40position: middledoi
Selective Elimination of Senescent Cancer Cells by Galacto-Modified PROTACs
Journal of Medicinal Chemistry 2024cited by 32position: middledoi
Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.
2024cited by 29position: contributordoi
Evaluation of the antitumor effect of neoantigen peptide vaccines derived from the translatome of lung cancer
Cancer Immunology Immunotherapy 2024cited by 3position: middledoi
Functional significance of cholesterol metabolism in cancer: from threat to treatment
Experimental & Molecular Medicine 2023cited by 193position: middledoi
Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation
Journal of the American Chemical Society 2023cited by 129position: middledoi
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
2023cited by 45position: contributordoi
Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach
Clinical Cancer Research 2023cited by 34position: middledoi
An Alternative Mechanism of Subcellular Iron Uptake Deficiency in Cardiomyocytes
Circulation Research 2023cited by 10position: middledoi
Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study.
2022cited by 47position: contributordoi
Building bioorthogonal click-release capable artificial receptors on cancer cell surface for imaging, drug targeting and delivery
Acta Pharmaceutica Sinica B 2022cited by 24position: middledoi
Deterministic evolution and stringent selection during pre-neoplasia
2022cited by 5position: contributordoi
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
2021cited by 217position: contributordoi
A CRISPR/Cas9-Engineered <i>ARID1A</i> -Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation
Cancer Discovery 2021cited by 165position: middledoi
A CRISPR/Cas9-Engineered <i>ARID1A</i>-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation.
2021cited by 131position: contributordoi
Cell of Origin Influences Pancreatic Cancer Subtype.
2021cited by 101position: contributordoi
Selection of metastasis competent subclones in the tumour interior.
2021cited by 65position: contributordoi
Spatial patterns of tumour growth impact clonal diversification: computational modelling and evidence in the TRACERx Renal study
2021cited by 0position: contributordoi
Pervasive chromosomal instability and karyotype order in tumour evolution
Nature 2020cited by 401position: middledoi
Pervasive chromosomal instability and karyotype order in tumour evolution.
2020cited by 302position: contributordoi
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity
Nature Communications 2020cited by 99position: middledoi
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity.
2020cited by 87position: contributordoi
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue
Cell Reports 2020cited by 75position: middledoi
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
2020cited by 59position: contributordoi
Evaluation of Two Primer Sets for Amplification of Comammox Nitrospira amoA Genes in Wetland Soils
Frontiers in Microbiology 2020cited by 14position: middledoi
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
Cell 2018cited by 664position: middledoi
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
Cell 2018cited by 555position: middledoi
The prognostic value of preoperative neutrophil-to-lymphocyte ratio in patients with upper tract urothelial carcinoma
Clinica Chimica Acta 2018cited by 30position: middledoi
Tracking the Evolution of Non–Small-Cell Lung Cancer
New England Journal of Medicine 2017cited by 2,410position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Charles Swanton · Cancer Evolution and Genome Instability Laboratory6 papers (2020–2022)James Larkin · Trinity College Dublin5 papers (2020–2022)Samra Turajlic · Institute of Cancer Research4 papers (2020–2022)Kevin Litchfield · Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory4 papers (2020–2022) · 4 papers (2020–2022) · 4 papers (2021–2022)Stuart Horswell · Newcastle University4 papers (2020–2022)Mengyang Chang · University of Arizona4 papers (2022–2024)Wei Wang · University of Alabama at Birmingham4 papers (2022–2024) · 3 papers (2021–2022) · 3 papers (2021–2022)Xiao Fu · Jiangxi University of Traditional Chinese Medicine3 papers (2021–2022)Christina Curtis · Duke University3 papers (2021–2022)Paul Bates · Centre National de la Recherche Scientifique3 papers (2021–2022)Jose I. López · Cedars-Sinai Medical Center3 papers (2021–2022) · 3 papers (2021–2022)Giri Gnawali · University of Arizona3 papers (2022–2024)Feng Gao · Hebei Medical University2 papers (2023–2024)Dow-Mu Koh · The University of Texas Southwestern Medical Center2 papers (2021–2022)Simon Doran · Royal Marsden NHS Foundation Trust2 papers (2021–2022)